CA2199642C - Compositions associant l'aspirine et un oligosaccharide anti-xa et utilisation d'un oligosaccharide anti-xa facultativement associe a l'aspirine - Google Patents

Compositions associant l'aspirine et un oligosaccharide anti-xa et utilisation d'un oligosaccharide anti-xa facultativement associe a l'aspirine Download PDF

Info

Publication number: CA2199642C
Authority: CA; Canada
Prior art keywords: oligosaccharide; aspirin; sulpho; alpha; sulphoamino
Prior art date: 1997-03-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002199642A

Other languages

English (en)

Other versions

CA2199642A1 (fr

Inventor

Roger Cariou

Jacobus Christianus Johannes Stiekema

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sanofi Aventis France

Original Assignee

Sanofi Synthelabo SA

Akzo Nobel NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-10

Filing date

1997-03-10

Publication date

2001-05-08

1997-03-10 Application filed by Sanofi Synthelabo SA, Akzo Nobel NV filed Critical Sanofi Synthelabo SA

1997-03-10 Priority to CA002199642A priority Critical patent/CA2199642C/fr

1997-03-13 Priority to EA199700025A priority patent/EA000048B1/ru

1997-03-14 Priority to AU16319/97A priority patent/AU698456B2/en

1997-03-17 Priority to BR9701313A priority patent/BR9701313A/pt

1998-09-10 Publication of CA2199642A1 publication Critical patent/CA2199642A1/fr

2001-05-08 Application granted granted Critical

2001-05-08 Publication of CA2199642C publication Critical patent/CA2199642C/fr

2017-03-10 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 38
229920001542 oligosaccharide Polymers 0.000 title claims abstract description 37
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims abstract description 32
229960001138 acetylsalicylic acid Drugs 0.000 title claims abstract description 32
239000000203 mixture Substances 0.000 title claims description 7
230000001858 anti-Xa Effects 0.000 title description 7
108010074860 Factor Xa Proteins 0.000 claims abstract description 16
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
238000002399 angioplasty Methods 0.000 claims abstract description 12
208000001435 Thromboembolism Diseases 0.000 claims abstract description 11
102000004411 Antithrombin III Human genes 0.000 claims abstract description 10
108090000935 Antithrombin III Proteins 0.000 claims abstract description 10
241000124008 Mammalia Species 0.000 claims abstract description 10
229940124639 Selective inhibitor Drugs 0.000 claims abstract description 10
229960005348 antithrombin iii Drugs 0.000 claims abstract description 10
239000003814 drug Substances 0.000 claims abstract description 7
238000002360 preparation method Methods 0.000 claims abstract description 5
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 3
150000003839 salts Chemical class 0.000 claims description 10
238000001990 intravenous administration Methods 0.000 claims description 7
XEKSTYNIJLDDAZ-JASSWCPGSA-F fondaparinux sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O[C@@H]1[C@@H](NS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OS([O-])(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS([O-])(=O)=O)O4)NS([O-])(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS([O-])(=O)=O)O2)NS([O-])(=O)=O)[C@H](C(O)=O)O1 XEKSTYNIJLDDAZ-JASSWCPGSA-F 0.000 claims description 6
150000001450 anions Chemical class 0.000 claims description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
238000007920 subcutaneous administration Methods 0.000 claims description 5
230000037396 body weight Effects 0.000 claims description 3
239000004480 active ingredient Substances 0.000 description 15
KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 11
108090000190 Thrombin Proteins 0.000 description 11
208000007536 Thrombosis Diseases 0.000 description 11
229960004072 thrombin Drugs 0.000 description 11
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 9
230000000694 effects Effects 0.000 description 8
229960002897 heparin Drugs 0.000 description 8
229920000669 heparin Polymers 0.000 description 8
239000002253 acid Substances 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
239000000243 solution Substances 0.000 description 5
206010003178 Arterial thrombosis Diseases 0.000 description 4
229920000858 Cyclodextrin Polymers 0.000 description 4
230000002785 anti-thrombosis Effects 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
241000282414 Homo sapiens Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000000034 method Methods 0.000 description 3
208000010125 myocardial infarction Diseases 0.000 description 3
230000002265 prevention Effects 0.000 description 3
-1 vinyl alcohols Chemical class 0.000 description 3
206010003210 Arteriosclerosis Diseases 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
239000004019 antithrombin Substances 0.000 description 2
208000011775 arteriosclerosis disease Diseases 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000023555 blood coagulation Effects 0.000 description 2
XEKSTYNIJLDDAZ-JASSWCPGSA-D decasodium;(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4-hydroxy-6-[(2r,3s,4r,5r,6s)-4-hydroxy-6-methoxy-5-(sulfonatoamino)-2-(sulfonatooxymethyl)oxan-3-yl]oxy-5-sulfonatooxyoxan-3-yl]oxy-5-(sulfonatoamino)-4-sulfonatooxy-2-(sul Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O[C@@H]1[C@@H](NS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OS([O-])(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS([O-])(=O)=O)O4)NS([O-])(=O)=O)[C@H](O3)C([O-])=O)O)[C@@H](COS([O-])(=O)=O)O2)NS([O-])(=O)=O)[C@H](C([O-])=O)O1 XEKSTYNIJLDDAZ-JASSWCPGSA-D 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
239000003055 low molecular weight heparin Substances 0.000 description 2
229940127215 low-molecular weight heparin Drugs 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000000843 powder Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000003868 thrombin inhibitor Substances 0.000 description 2
230000001732 thrombotic effect Effects 0.000 description 2
229920002554 vinyl polymer Polymers 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
206010002388 Angina unstable Diseases 0.000 description 1
200000000007 Arterial disease Diseases 0.000 description 1
239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
229940123900 Direct thrombin inhibitor Drugs 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
108010029144 Factor IIa Proteins 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
208000007718 Stable Angina Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
229940122388 Thrombin inhibitor Drugs 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
208000007814 Unstable Angina Diseases 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
150000001253 acrylic acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
229960003318 alteplase Drugs 0.000 description 1
238000002583 angiography Methods 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000002224 dissection Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000010102 embolization Effects 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
201000004332 intermediate coronary syndrome Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
108010041201 prothrombin fragment 1 Proteins 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
229960005001 ticlopidine Drugs 0.000 description 1
230000002792 vascular Effects 0.000 description 1
229920006163 vinyl copolymer Polymers 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002199642A 1997-03-10 1997-03-10 Compositions associant l'aspirine et un oligosaccharide anti-xa et utilisation d'un oligosaccharide anti-xa facultativement associe a l'aspirine Expired - Lifetime CA2199642C (fr)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
CA002199642A CA2199642C (fr)	1997-03-10	1997-03-10	Compositions associant l'aspirine et un oligosaccharide anti-xa et utilisation d'un oligosaccharide anti-xa facultativement associe a l'aspirine
EA199700025A EA000048B1 (ru)	1997-03-10	1997-03-13	Применение олигосахарида и аспирина для лечения тромбоэболических заболеваний, фармацевтическая композиция, способ лечения
AU16319/97A AU698456B2 (en)	1997-03-10	1997-03-14	Compositions containing an association of aspirin and an anti-Xa oligosaccharide and use of anti-Xa oligosaccharide optionally in combination with aspirin
BR9701313A BR9701313A (pt)	1997-03-10	1997-03-17	Composições que contêm uma associação de aspririna e um oligossacarídeo anti-xa e uso de um olissacarídeo anti-xa opicionalmente em combinação com aspirina

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CA002199642A CA2199642C (fr)	1997-03-10	1997-03-10	Compositions associant l'aspirine et un oligosaccharide anti-xa et utilisation d'un oligosaccharide anti-xa facultativement associe a l'aspirine
AU16319/97A AU698456B2 (en)	1997-03-10	1997-03-14	Compositions containing an association of aspirin and an anti-Xa oligosaccharide and use of anti-Xa oligosaccharide optionally in combination with aspirin
BR9701313A BR9701313A (pt)	1997-03-10	1997-03-17	Composições que contêm uma associação de aspririna e um oligossacarídeo anti-xa e uso de um olissacarídeo anti-xa opicionalmente em combinação com aspirina

Publications (2)

Publication Number	Publication Date
CA2199642A1 CA2199642A1 (fr)	1998-09-10
CA2199642C true CA2199642C (fr)	2001-05-08

Family

ID=27152254

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002199642A Expired - Lifetime CA2199642C (fr)	1997-03-10	1997-03-10	Compositions associant l'aspirine et un oligosaccharide anti-xa et utilisation d'un oligosaccharide anti-xa facultativement associe a l'aspirine

Country Status (4)

Country	Link
AU (1)	AU698456B2 (fr)
BR (1)	BR9701313A (fr)
CA (1)	CA2199642C (fr)
EA (1)	EA000048B1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6794412B1 (en) *	1999-03-11	2004-09-21	Bristol-Myers Squibb Pharma Company	Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
UA80399C2 (en) *	2001-11-13	2007-09-25	Glaxo Group Ltd	Use of specific dose of fondaparinux sodium for the treatment of acs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2564468B1 (fr) *	1984-05-16	1994-12-23	Choay Sa	Nouveaux oligosaccharides, leur preparation par voie de synthese et leurs applications biologiques
AU563351C (en) *	1982-01-15	2003-06-19	Glaxo Group Limited	Synthesis of oligosaccharides

1997
- 1997-03-10 CA CA002199642A patent/CA2199642C/fr not_active Expired - Lifetime
- 1997-03-13 EA EA199700025A patent/EA000048B1/ru not_active IP Right Cessation
- 1997-03-14 AU AU16319/97A patent/AU698456B2/en not_active Expired
- 1997-03-17 BR BR9701313A patent/BR9701313A/pt not_active Application Discontinuation

Also Published As

Publication number	Publication date
BR9701313A (pt)	1998-11-17
EA000048B1 (ru)	1998-04-30
AU1631997A (en)	1998-09-17
CA2199642A1 (fr)	1998-09-10
AU698456B2 (en)	1998-10-29
EA199700025A1 (ru)	1997-12-30

Publication	Publication Date	Title
RU2184547C2 (ru)	2002-07-10	Новые соединения действующих начал, содержащих клопидогрел, и антитромбическое средство
Brugieres et al.	1989	Hemorrhagic cystitis following high-dose chemotherapy and bone marrow transplantation in children with malignancies: incidence, clinical course, and outcome.
Herbert et al.	2001	SR123781A, a synthetic heparin mimetic
NO323739B1 (no)	2007-07-02	Preparater for behandling og forebygging av arteriell trombose og anvendelse av en faktor Xa inhibitor kombinert med et antiblodplateaggregeringsmiddel
US20060040896A1 (en)	2006-02-23	Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
AU781691B2 (en)	2005-06-09	Pharmaceutical combinations
WO2000064470A1 (fr)	2000-11-02	Formulation pharmaceutique comportant un inhibiteur de thrombine de faible poids moleculaire et son promedicament
JP3813169B2 (ja)	2006-08-23	抗血栓剤
Matsuo et al.	1997	Development of argatroban, a direct thrombin inhibitor, and its clinical application
Rogers et al.	1976	Current status of antithrombotic therapy in cardiovascular disease
Beijering et al.	1996	Clinical applications of new antithrombotic agents
CH661439A5 (it)	1987-07-31	Glicosaminoglicani modificati dotati di attivita antitrombotica.
CA2199642C (fr)	2001-05-08	Compositions associant l'aspirine et un oligosaccharide anti-xa et utilisation d'un oligosaccharide anti-xa facultativement associe a l'aspirine
US20060122151A1 (en)	2006-06-08	Composition containing an association of aspirin and an anti-Xa oligosaccharide and use of an anti-Xa oligosaccharide optionally in combination with aspirin
JP3169343B2 (ja)	2001-05-21	アスピリンおよび抗−Ｘａオリゴ糖の組合せを含有する組成物ならびにアスピリンと任意的に組み合わせた抗−Ｘａオリゴ糖の使用
US6828307B1 (en)	2004-12-07	Low molecular weight sulphated polysaccharide to obtain a medicine with antithrombotic activity
MXPA97001943A (en)	1998-11-16	Compositions containing an acetilsalicilic acid association and an anti-xa oligosacarid and use of an anti-xa oligosacaride optionally in combination with acetilsalicil acid
WO2012158003A1 (fr)	2012-11-22	Nouvel inhibiteur du facteur xii
KR100231978B1 (ko)	1999-12-01	아스피린 회합체 및 안티-Xa 올리고사카라이드를 함유하는 조성물과 아스피린 결합물내 안티-XA 올리고사카라이드의 용도
Niada et al.	1986	Protective activity of defibrotide against lethal acute myocardial ischemia in the cat
US20040214751A1 (en)	2004-10-28	Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients
AU2001291549A1 (en)	2002-03-22	Antithrombotic compositions
AU2002363023B2 (en)	2007-10-25	A combination product comprising melagatran and dexamethasone
AU707215B2 (en)	1999-07-08	Thrombolytic agents
Bevilacqua et al.	1991	Acute carotid artery occlusive thrombosis and its pharmacological prevention in the rabbit

Legal Events

Date	Code	Title	Description
1997-03-10	EEER	Examination request
2017-05-14	MKEX	Expiry	Effective date: 20170310